BioStock: BioInvent presents positive interim data

BioInvent has presented updated positive interim data from its phase I/II study with the anti-FcyRIIB antibody BI-1206. The current study evaluates BI-1206 in combination with rituximab for the treatment of patients with indolent non-Hodgkin's B-cell lymphoma. BioInvent will hold a Key Opinion Leader event on December 17 where this data will be discussed in more detail.

Read the full article about BioInvent at biostock.se:

https://www.biostock.se/en/2021/12/bioinvent-presents-positive-interim-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/